These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22098708)

  • 1. Bed rest or mobilization after rt-PA? A case-crossover study of factors influencing clinical decision making in stroke services.
    Ha J; Churilov L; Linden T; Bernhardt J
    Int J Stroke; 2013 Apr; 8(3):172-9. PubMed ID: 22098708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
    National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group
    Ann Emerg Med; 2005 Sep; 46(3):243-52. PubMed ID: 16126134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group.
    Kwiatkowski TG; Libman RB; Frankel M; Tilley BC; Morgenstern LB; Lu M; Broderick JP; Lewandowski CA; Marler JR; Levine SR; Brott T
    N Engl J Med; 1999 Jun; 340(23):1781-7. PubMed ID: 10362821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry.
    Mori M; Naganuma M; Okada Y; Hasegawa Y; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Kario K; Okuda S; Koga M; Minematsu K; Toyoda K
    Cerebrovasc Dis; 2012; 34(2):140-6. PubMed ID: 22854333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke: initial Israeli experience.
    Schwammenthal Y; Drescher MJ; Merzeliak O; Tsabari R; Bruk B; Feibel M; Hoffman C; Bakon M; Rotstein Z; Chapman J; Tanne D
    Isr Med Assoc J; 2004 Feb; 6(2):70-4. PubMed ID: 14986460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agreement with evidence for tissue Plasminogen Activator use among emergency physicians: a cross-sectional survey.
    Grady AM; Bryant J; Carey ML; Paul CL; Sanson-Fisher RW; Levi CR
    BMC Res Notes; 2015 Jun; 8():267. PubMed ID: 26111807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is intravenous recombinant tissue plasminogen activator (rt-PA) safe for use in patients over 80 years old with acute ischaemic stroke? - The Calgary experience.
    Simon JE; Sandler DL; Pexman JH; Hill MD; Buchan AM;
    Age Ageing; 2004 Mar; 33(2):143-9. PubMed ID: 14960429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing number of stroke specialists should contribute to utilization of IV rt-PA: results of questionnaires from 1,466 hospitals in Japan.
    Iguchi Y; Kimura K; Shibazaki K; Iwanaga T
    J Neurol Sci; 2009 Apr; 279(1-2):66-9. PubMed ID: 19185882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of serum lipid levels on stroke outcome after rt-PA therapy: SAMURAI rt-PA registry.
    Makihara N; Okada Y; Koga M; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Hasegawa Y; Kario K; Okuda S; Naganuma M; Toyoda K
    Cerebrovasc Dis; 2012; 33(3):240-7. PubMed ID: 22261711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of acute nonthrombolytic and thrombolytic treatments in ischemic stroke patients 80 years or older.
    Zacharatos H; Hassan AE; Vazquez G; Hussein HM; Rodriguez GJ; Suri MF; Lakshminarayan K; Ezzeddine MA; Qureshi AI
    Am J Emerg Med; 2012 Jan; 30(1):158-64. PubMed ID: 21247724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of combined venous and arterial thrombolysis with primary arterial therapy using recombinant tissue plasminogen activator in acute ischemic stroke.
    Wolfe T; Suarez JI; Tarr RW; Welter E; Landis D; Sunshine JL; Zaidat OO
    J Stroke Cerebrovasc Dis; 2008; 17(3):121-8. PubMed ID: 18436152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous thrombolysis in German stroke units before and after regulatory approval of recombinant tissue plasminogen activator.
    Weimar C; Kraywinkel K; Maschke M; Diener HC;
    Cerebrovasc Dis; 2006; 22(5-6):429-31. PubMed ID: 16912477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes among stroke patients receiving tissue plasminogen activator therapy beyond the 3-hour time window.
    O'Brien EC; Rose KM; Patel MD; Murphy CV; Rosamond WD
    J Stroke Cerebrovasc Dis; 2012 Oct; 21(7):541-6. PubMed ID: 21236701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intravenous tissue plasminogen activator in the treatment of acute ischemic stroke: feasibility, safety, and efficiency in the 2 first years of the clinical practice].
    Feuerhake W; Chamorro H; Araya F
    Rev Med Chil; 1999 Jul; 127(7):814-9. PubMed ID: 10668289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilization of intravenous thrombolysis in 3-4.5 hours: analysis of the Minnesota stroke registry.
    Tekle WG; Chaudhry SA; Hassan AE; Peacock JM; Lakshminarayan K; Tsai A; Luepker R; Anderson DC; Qureshi AI
    Cerebrovasc Dis; 2012; 34(5-6):400-5. PubMed ID: 23221276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke.
    Brown DL; Barsan WG; Lisabeth LD; Gallery ME; Morgenstern LB
    Ann Emerg Med; 2005 Jul; 46(1):56-60. PubMed ID: 15988427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment ASPECTS on DWI predicts 3-month outcome following rt-PA: SAMURAI rt-PA Registry.
    Nezu T; Koga M; Kimura K; Shiokawa Y; Nakagawara J; Furui E; Yamagami H; Okada Y; Hasegawa Y; Kario K; Okuda S; Nishiyama K; Naganuma M; Minematsu K; Toyoda K
    Neurology; 2010 Aug; 75(6):555-61. PubMed ID: 20697108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Life-threatening anaphylactoid shock caused by recombinant tissue plasminogen activator.
    Wang CT; Lin FC; Khor GT; Chen CH; Huang P
    Am J Emerg Med; 2012 Jan; 30(1):253.e1-2. PubMed ID: 21109385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. To treat or not to treat? Pilot survey for minor and rapidly improving stroke.
    Balucani C; Bianchi R; Feldmann E; Weedon J; Kolychev D; Levine SR
    Stroke; 2015 Mar; 46(3):874-6. PubMed ID: 25604250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of pediatric stroke with recombinant tissue plasminogen activator (rt-PA): a case report and review of the literature.
    Cremer S; Berliner Y; Warren D; Jones AE
    CJEM; 2008 Nov; 10(6):575-8. PubMed ID: 19000355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.